|
|
|
Insider
Information: |
Orbimed Capital Llc |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
12 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
39,063,801 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$85,348,806 |
|
|
Total
Shares |
39,063,801 |
|
|
Total
Value |
$85,348,806 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
2
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
1
|
2
|
|
|
|
Gain/Loss Ratio : |
-1.0
|
-2.0
|
Percentage
Gain/Loss : |
-31.6%
|
-98.7%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Orthovita Inc |
VITA |
10% Owner |
2003-07-22 |
0 |
2004-01-14 |
5,350,000 |
Premium* |
|
American Cryostem Corporation |
CRYO |
10% Owner |
2007-06-14 |
0 |
2007-06-14 |
389,432 |
Premium* |
|
Alector, Inc. |
ALEC |
10% Owner |
2019-02-11 |
0 |
2020-03-02 |
0 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2020-01-29 |
0 |
2020-01-29 |
1,477,320 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
Director |
2020-06-23 |
0 |
2021-09-07 |
96,190 |
Premium* |
|
Fusion Pharmaceuticals Inc. |
FUSN |
Director |
2020-06-30 |
0 |
2020-06-30 |
192,100 |
Premium* |
|
Prelude Therapeutics Inc |
PRLD |
Director, 10% Owner |
2020-09-25 |
0 |
2023-05-22 |
10,646,056 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2020-09-29 |
0 |
2022-03-31 |
6,589,330 |
Premium* |
|
Kinnate Biopharma Inc. |
KNTE |
Director, 10% Owner |
2020-12-02 |
0 |
2024-04-03 |
0 |
Premium* |
|
Silverback Therapeutics, Inc. |
SBTX |
Director |
2020-12-08 |
0 |
2023-08-29 |
9,240,887 |
Premium* |
|
Decibel Therapeutics, Inc. |
DBTX |
Director, 10% Owner |
2021-02-17 |
0 |
2021-02-17 |
883,418 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Director, 10% Owner |
2021-07-16 |
0 |
2021-07-16 |
4,199,068 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2024-04-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,009,729) |
0 |
0 |
- |
|
SBTX |
Silverback Therapeutics, ... |
Director |
|
2023-08-29 |
4 |
B |
$6.20 |
$3,100,000 |
I/I |
500,000 |
8,019,187 |
2.1 |
- |
|
PRLD |
Prelude Therapeutics Inc |
Director |
|
2023-05-22 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
10,119,756 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2023-05-05 |
4 |
B |
$2.82 |
$2,766,485 |
I/I |
981,023 |
1,368,338 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2023-05-04 |
4 |
B |
$2.75 |
$1,319,750 |
I/I |
479,909 |
877,827 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2023-05-02 |
4 |
B |
$2.67 |
$903,160 |
I/I |
338,262 |
794,368 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2023-05-01 |
4 |
B |
$2.62 |
$1,876,331 |
I/I |
716,157 |
735,542 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2023-04-28 |
4 |
B |
$2.55 |
$894,410 |
I/I |
350,749 |
610,997 |
2.25 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,100,000 |
550,000 |
0 |
- |
|
PMVP |
Pmv Pharmaceuticals, Inc. |
10% Owner |
|
2022-03-31 |
4 |
S |
$21.17 |
$730,365 |
I/I |
(34,500) |
0 |
0 |
- |
|
PMVP |
Pmv Pharmaceuticals, Inc. |
10% Owner |
|
2022-03-30 |
4 |
S |
$22.39 |
$1,679,250 |
I/I |
(75,000) |
34,500 |
0 |
- |
|
PMVP |
Pmv Pharmaceuticals, Inc. |
10% Owner |
|
2022-03-29 |
4 |
S |
$21.52 |
$7,854,800 |
I/I |
(365,000) |
109,500 |
0 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2022-02-15 |
4 |
B |
$9.96 |
$89,640 |
I/I |
9,000 |
3,509,030 |
2.1 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2022-02-14 |
4 |
B |
$9.89 |
$305,486 |
I/I |
30,700 |
3,500,030 |
2.1 |
- |
|
KNTE |
Kinnate Biopharma Inc. |
Director |
|
2022-02-11 |
4 |
B |
$10.22 |
$1,594,320 |
I/I |
156,000 |
3,469,330 |
2.1 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-09-07 |
4 |
AS |
$33.93 |
$30,096 |
I/I |
(887) |
96,190 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-09-03 |
4 |
AS |
$34.00 |
$244,698 |
I/I |
(7,197) |
96,216 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-09-02 |
4 |
AS |
$34.24 |
$562,358 |
I/I |
(16,424) |
96,428 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-09-01 |
4 |
AS |
$33.98 |
$440,653 |
I/I |
(12,968) |
96,911 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-08-31 |
4 |
AS |
$33.94 |
$287,540 |
I/I |
(8,472) |
97,293 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-08-30 |
4 |
AS |
$33.92 |
$227,162 |
I/I |
(6,697) |
97,542 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-08-27 |
4 |
AS |
$33.94 |
$240,736 |
I/I |
(7,093) |
97,739 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-08-26 |
4 |
AS |
$34.52 |
$147,849 |
I/I |
(4,283) |
97,948 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-08-25 |
4 |
AS |
$34.34 |
$243,196 |
I/I |
(7,082) |
98,074 |
0 |
- |
|
RPTX |
Repare Therapeutics Inc. |
Director |
|
2021-08-24 |
4 |
AS |
$34.07 |
$137,609 |
I/I |
(4,039) |
98,282 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|